Cwm LLC Sells 3,323 Shares of Sanofi (NASDAQ:SNY)

Cwm LLC reduced its position in Sanofi (NASDAQ:SNY) by 2.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 134,827 shares of the company’s stock after selling 3,323 shares during the quarter. Cwm LLC’s holdings in Sanofi were worth $6,705,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Rise Advisors LLC boosted its position in shares of Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the period. Salem Investment Counselors Inc. bought a new position in shares of Sanofi in the fourth quarter valued at approximately $27,000. Venturi Wealth Management LLC lifted its position in Sanofi by 163.5% during the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after purchasing an additional 332 shares during the last quarter. CNB Bank bought a new stake in Sanofi during the third quarter valued at approximately $39,000. Finally, Farmers & Merchants Trust Co of Chambersburg PA lifted its position in Sanofi by 115.6% during the fourth quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after purchasing an additional 400 shares during the last quarter. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Shares of SNY stock opened at $47.15 on Tuesday. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.82. The stock has a market cap of $119.27 billion, a PE ratio of 19.98, a price-to-earnings-growth ratio of 1.62 and a beta of 0.61. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company’s fifty day moving average price is $47.54 and its 200-day moving average price is $48.50.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. On average, equities analysts expect that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a $1.478 dividend. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s payout ratio is 58.47%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Morgan Stanley initiated coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target on the stock. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.